01 / 01

REGEnLIFE

REGEnLIFE presents first results of pilot clinical trial evaluating photobiomodulation technology in the treatment of Alzheimer’s disease

REGEnLIFE presents first results of pilot clinical trial evaluating photobiomodulation technology in the treatment of Alzheimer’s disease Within treated patient group, trends showed improved cognitive and executive functions, improved language comprehension and verbal memory, in comparison to placebo group REGEnLIFE’s technology shown to be safe and well-tolerated by patients Initial...

Mar , 17
REGEnLIFE presenting at ‘AAT-AD/PD’ Congress in Torino

REGEnLIFE presenting at ‘AAT-AD/PD’ Congress in Torino

REGEnLIFE participated at ‘Advances in Alzheimer’s and Parkinson’s Therapies’  Congress in Torino, Italy, and presented a poster of ‘Neuroprotective effect of a new photo-biomodulation technique against amyloid Aβ25-35 peptide induced toxicity in mice might support : a novel hypothesis for therapeutic approach of Alzheimer’s disease’ study....

Mar , 15
THINKING OUTSIDE THE BOX

THINKING OUTSIDE THE BOX

REGEnLIFE presentation selected for the highlights of the ‘Clinical Trials on Alzheimer’s Disease’ (CTAD) international conference Read PDF...

Nov , 4